S&P 500   4,298.86
DOW   33,876.78
QQQ   354.50
MarketBeat Week in Review – 6/4 - 6/9
BREAKING: Tiny biotech successfully treats blindness (Ad)
FuelCell Is Back To Realistic Valuation
New Mexico reaches $500M settlement with Walgreens in opioid case
Trade Smarter: Discover Hidden Opportunities w/ A.I. (Ad)
Nigeria's central bank chief arrested after being suspended by president
American Airlines, JetBlue seek to keep some ties despite losing antitrust case
Trade Smarter: Discover Hidden Opportunities w/ A.I. (Ad)
North Dakota tribe buys idle oil pipeline from Enbridge
Ukrainian President Volodymyr Zelenskyy says ‘counteroffensive, defensive actions’ taking place in war with Russia
S&P 500   4,298.86
DOW   33,876.78
QQQ   354.50
MarketBeat Week in Review – 6/4 - 6/9
BREAKING: Tiny biotech successfully treats blindness (Ad)
FuelCell Is Back To Realistic Valuation
New Mexico reaches $500M settlement with Walgreens in opioid case
Trade Smarter: Discover Hidden Opportunities w/ A.I. (Ad)
Nigeria's central bank chief arrested after being suspended by president
American Airlines, JetBlue seek to keep some ties despite losing antitrust case
Trade Smarter: Discover Hidden Opportunities w/ A.I. (Ad)
North Dakota tribe buys idle oil pipeline from Enbridge
Ukrainian President Volodymyr Zelenskyy says ‘counteroffensive, defensive actions’ taking place in war with Russia
S&P 500   4,298.86
DOW   33,876.78
QQQ   354.50
MarketBeat Week in Review – 6/4 - 6/9
BREAKING: Tiny biotech successfully treats blindness (Ad)
FuelCell Is Back To Realistic Valuation
New Mexico reaches $500M settlement with Walgreens in opioid case
Trade Smarter: Discover Hidden Opportunities w/ A.I. (Ad)
Nigeria's central bank chief arrested after being suspended by president
American Airlines, JetBlue seek to keep some ties despite losing antitrust case
Trade Smarter: Discover Hidden Opportunities w/ A.I. (Ad)
North Dakota tribe buys idle oil pipeline from Enbridge
Ukrainian President Volodymyr Zelenskyy says ‘counteroffensive, defensive actions’ taking place in war with Russia
S&P 500   4,298.86
DOW   33,876.78
QQQ   354.50
MarketBeat Week in Review – 6/4 - 6/9
BREAKING: Tiny biotech successfully treats blindness (Ad)
FuelCell Is Back To Realistic Valuation
New Mexico reaches $500M settlement with Walgreens in opioid case
Trade Smarter: Discover Hidden Opportunities w/ A.I. (Ad)
Nigeria's central bank chief arrested after being suspended by president
American Airlines, JetBlue seek to keep some ties despite losing antitrust case
Trade Smarter: Discover Hidden Opportunities w/ A.I. (Ad)
North Dakota tribe buys idle oil pipeline from Enbridge
Ukrainian President Volodymyr Zelenskyy says ‘counteroffensive, defensive actions’ taking place in war with Russia
NASDAQ:ISO

IsoPlexis (ISO) Stock Forecast, Price & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
Compare
Today's Range
$0.76
$0.76
50-Day Range
$0.74
$1.13
52-Week Range
$0.60
$5.10
Volume
N/A
Average Volume
68,375 shs
Market Capitalization
$30.28 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$1.60

ISO stock logo

About IsoPlexis (NASDAQ:ISO) Stock

IsoPlexis Corporation, a life sciences company, provides solutions for the development of curative medicines and personalized therapeutics in the United States, Canada, the United Kingdom, Belgium, France, the Czech Republic, Spain, Germany, Sweden, Italy, Israel, Switzerland, China and Taiwan, Singapore, Japan, Australia, and Korea. The company offers single cell proteomics platform, including instruments, chip consumables, and software that provides an end-to-end solution to view of protein function at an individual cellular level. It provides IsoLight and IsoSpark instruments; IsoCode chips that offer multiplexed chip solutions for single cell functional proteomics; CodePlex chips that provide multiplexed solutions for ultra-low volume bulk samples; and IsoSpeak software that offers dimensional data and automates analysis with an intuitive push button user interface to deliver same day single cell and bulk proteome visualizations, as well as research support and services, and post-warranty services. The company was incorporated in 2013 and is based in Branford, Connecticut.

Receive ISO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for IsoPlexis and its competitors with MarketBeat's FREE daily newsletter.

ISO Stock News Headlines

10-Q: PHENOMEX INC.
PhenomeX Reports First Quarter 2023 Financial Results
[BREAKING] New "Living Software" to Revolutionize Warfare
This breakthrough will change "the way wars will be fought, and won, for years to come." - Chairman of the Joint Chief of Staff, General Mark Milley Get the name of the company supplying it to the U.S. Army here >>>
Contrasting IsoPlexis (ISO) and Its Competitors
IsoPlexis (ISO) & Its Competitors Critical Contrast
[BREAKING] New "Living Software" to Revolutionize Warfare
This breakthrough will change "the way wars will be fought, and won, for years to come." - Chairman of the Joint Chief of Staff, General Mark Milley Get the name of the company supplying it to the U.S. Army here >>>
IsoPlexis (ISO) and Its Peers Head to Head Review
Critical Survey: IsoPlexis (ISO) vs. Its Peers
Contrasting IsoPlexis (ISO) and The Competition
Analyzing IsoPlexis (ISO) and The Competition
IsoPlexis (ISO) and Its Competitors Head-To-Head Analysis
PhenomeX Strengthens Commercial Leadership Team
IsoPlexis Reports Preliminary Full Year 2022 Revenue
See More Headlines


ISO Company Calendar

Last Earnings
11/10/2021
Today
6/10/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Analytical instruments
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ISO
Fax
N/A
Employees
459
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$1.60
High Stock Price Forecast
$1.70
Low Stock Price Forecast
$1.50
Forecasted Upside/Downside
+110.1%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
2 Analysts

Profitability

Net Income
$-106,000,000.00
Net Margins
-632.41%
Pretax Margin
-632.40%

Debt

Sales & Book Value

Annual Sales
$16.76 million
Book Value
$1.04 per share

Miscellaneous

Free Float
37,218,000
Market Cap
$30.28 million
Optionable
Not Optionable
Beta
1.32

Key Executives

  • Mr. Sean Mackay (Age 40)
    Co-Founder, CEO, Pres & Director
    Comp: $635.55k
  • Mr. John R. Strahley CPA (Age 55)
    Chief Financial Officer
    Comp: $444.11k
  • Mr. Rong Fan
    Co-Founder & Chairman of Scientific Advisory Board
  • Mr. Jon Chen
    VP of Scientific Alliance Technology & Co-Founder
  • Mr. Anthony Catalano
    Sr. VP of Operations
  • Mr. Rajesh T. Khakhar
    VP of Fin. & Principal Accounting Officer
  • Ms. Jing Zhou M.D. (Age 52)
    Ph.D., Chief Scientific Officer
  • Mr. Richard W. Rew II (Age 54)
    Sr. VP, Gen. Counsel & Sec.
  • Ms. Verna Siu
    Sr. VP of Sales Operations
  • Ms. Carrie Carter
    Sr. VP of People Operations













ISO Stock - Frequently Asked Questions

Should I buy or sell IsoPlexis stock right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for IsoPlexis in the last twelve months. There are currently 2 hold ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" ISO shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ISO, but not buy additional shares or sell existing shares.
View ISO analyst ratings
or view top-rated stocks.

What is IsoPlexis' stock price forecast for 2023?

2 Wall Street research analysts have issued 12-month price objectives for IsoPlexis' stock. Their ISO share price forecasts range from $1.50 to $1.70. On average, they expect the company's stock price to reach $1.60 in the next twelve months. This suggests a possible upside of 110.1% from the stock's current price.
View analysts price targets for ISO
or view top-rated stocks among Wall Street analysts.

How were IsoPlexis' earnings last quarter?

IsoPlexis Co. (NASDAQ:ISO) posted its quarterly earnings results on Wednesday, November, 10th. The company reported ($10.66) EPS for the quarter, missing analysts' consensus estimates of ($0.79) by $9.87. The company had revenue of $4.19 million for the quarter, compared to the consensus estimate of $3.79 million. IsoPlexis had a negative net margin of 632.41% and a negative trailing twelve-month return on equity of 127.86%.

When did IsoPlexis IPO?

(ISO) raised $125 million in an initial public offering on Friday, October 8th 2021. The company issued 8,333,000 shares at $14.00-$16.00 per share.

What is IsoPlexis' stock symbol?

IsoPlexis trades on the NASDAQ under the ticker symbol "ISO."

What is IsoPlexis' stock price today?

One share of ISO stock can currently be purchased for approximately $0.76.

How much money does IsoPlexis make?

IsoPlexis (NASDAQ:ISO) has a market capitalization of $30.28 million and generates $16.76 million in revenue each year. The company earns $-106,000,000.00 in net income (profit) each year or ($2.70) on an earnings per share basis.

How many employees does IsoPlexis have?

The company employs 459 workers across the globe.

How can I contact IsoPlexis?

IsoPlexis' mailing address is 35 NE INDUSTRIAL ROAD, BRANFORD CT, 06405. The official website for the company is isoplexis.com. The company can be reached via phone at 203-208-4111 or via email at investors@isoplexis.com.

This page (NASDAQ:ISO) was last updated on 6/10/2023 by MarketBeat.com Staff

My Account -